TABLES

| S.1. | Signs and Symptoms of Agent Exposure | xxiii |
|------|---|-------|
| 1.1. | Symptom Frequency for 18,495 Gulf War Veterans Evaluated in the Comprehensive Clinical Evaluation Program | 4 |
| 3.1. | Lewisite: Attributes and Responses | 19 |
| 3.2. | Incapacitating Levels of Lewisite | 21 |
| 3.3. | Chemical and Physical Properties of Phosgene Oxime | 28 |
| 3.4. | Chemical and Physical Properties of Sulfur Mustard | 33 |
| 3.5. | Effects of Exposure to Mustards (H or HD) | 41 |
| 4.1. | Relative Lethalities of Selected Natural and Synthetic Poisons | 54 |
| 4.2. | Comparative Lethality of Some Toxins and Chemical Agents in Mice | 57 |
| 4.3. | Exposure Effects of Ricin | 62 |
| 4.4. | Effects of Varied Trichothecene (T-2) Exposures | 76 |
| 5.1. | Nerve Agent Chemical Structure | 108 |
| 5.2. | Persistence of Nerve Agents | 111 |
| 5.3. | Anticholinesterase Potency of Organophosphates | 118 |
| 5.4. | Estimates of Nerve Agent Lethality or Incapacitation to Humans | 127 |
| 5.5. | Nerve Agent Exposure Limits Established by the U.S. Army Surgeon General | 128 |

| 5.6. | Molar Concentration of Agent Required to Inhibit Half of Enzyme Activity | 137 |
|-------|--|-----|
| 5.7. | Results of Other Delayed-Neuropathy Studies | 138 |
| 5.8. | Signs and Symptoms Following Short-Term Nerve Agent Exposure | 141 |
| 5.9. | Severity Classifications for Organophosphate Pesticide Poisoning | 142 |
| 5.10. | Signs and Symptoms in Patients with Moderate to Severe Sarin Exposure | 143 |
| 5.11. | Incidence of Symptoms in Workers Accidentally Exposed to Tabun and Sarin (mild cases) | 144 |
| 5.12. | Signs and Symptoms of Dermal Exposures to Nerve Agents | 151 |
| 5.13. | Summary of Published Work on Chronic Effects of Long- Term Exposure to Small or Subclinical Organophosphate Quantities | 161 |
| 5.14. | Summary of Published Work on Delayed Effects of Acute or Symptomatic Organophosphate Intoxications | 162 |
| 5.15. | Estimates of Threshold Levels for Eye Effects of Selected Nerve Agents | 183 |
| 5.16. | Estimates of Incapacitating Levels of Selected Nerve Agents | 183 |
| B.1. | Chemical and Physical Properties of Tabun | 196 |
| B.2. | Chemical and Physical Properties of Sarin | 197 |
| В.3. | Chemical and Physical Properties of Soman | 198 |
| B.4. | Chemical and Physical Properties of Cyclosarin | 199 |
| B.5. | Chemical and Physical Properties of Thiosarin | 200 |
| B.6. | Chemical and Physical Properties of VX | 201 |
| B.7. | Dermal Exposures to Nerve Agent Required for Lethality to Humans | 202 |
| B.8. | Dermal Exposures to Nerve Agent: Other Effect Thresholds for Humans | 202 |
| B.9. | Exposures to Nerve Agent Vapor Required for Lethality or Incapacitation of Rhesus Monkeys | 203 |

| B.10. | Animal Performance Effects of Nerve Agent Exposures | 203 |
|-------|--|-----|
| B.11. | Signs and Symptoms Comparison, Percentage Reduction in AChE Activity | 204 |

Tables

xvii